Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the Symptomatic Treatment of Adults With Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice

Trial Profile

A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX for the Symptomatic Treatment of Adults With Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms REPOSE
  • Sponsors AbbVie; Allergan
  • Most Recent Events

    • 06 Jun 2021 Results assessing efficacy and safety parameters of 155- 195U onabotulinumtoxinA in participants with chronic migraine from the real- world REPOSE study, presented at the 63rd Annual Scientific Meeting of the American Headache Society.
    • 22 Apr 2021 Results assessing the efficacy and safety of onabotulinumtoxinA in participants with chronic migraine, presented at the 73rd Annual Meeting of the American Academy of Neurology.
    • 15 Jan 2021 According to an AbbVie media release, Allergan Aesthetics and Allergan will present data from this trial at the TOXINS 2021 Virtual Conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top